Dietary salt reduction or exclusion for allergic asthma.

BACKGROUND: There is a wide geographical variation in asthma prevalence and one explanation may be in dietary salt consumption. OBJECTIVES: To assess the effect of dietary sodium reduction in patients with asthma. SEARCH STRATEGY: A search was conducted using the Cochrane Airways Group asthma register. Bibliographies of included randomised controlled trials (RCTs) were searched for additional studies. Authors of identified RCTs were contacted for other studies. The most recent search was carried out in February 2004. SELECTION CRITERIA: All studies were to be RCTs that involved dietary salt reduction or increased salt intake in patients with asthma. Studies of other allergic conditions such as hay fever, allergic rhinitis and eczema were considered patients with asthma were separately identified. DATA COLLECTION AND ANALYSIS: Study quality was assessed and data extracted by two reviewers. All data analysis was conducted using the Cochrane Collaboration software (RevMan). MAIN RESULTS: Six RCTs were included in this review. All studies were small size and of short duration. Data from only four studies could be pooled. Low sodium diet was associated with a significantly lower urine sodium excretion than normal or high salt diets. There were no significant differences in any asthma outcome between low salt and normal or high salt diets, however the confidence intervals were wide. FEV(1) with low salt compared to normal diet showed a WMD 0.09 L with a 95% confidence interval (95%CI) -0.19 L to 0.38 L, and compared to a high salt diet WMD 0.18 L; 95%CI -0.11 L to 0.48 L. Daily PEFR was also non-significantly higher with low salt diet compared to normal (WMD 19.52 L/min; 95% CI -21.22 to 60.25) and high salt diet (WMD 7.57 L/min; 95% CI -37.52 to 52.67). Reliever bronchodilator with the low salt diet when compared to both the normal and high salt diets showed WMD -0.07 puffs/day; 95%CI -0.94 to 0.81 & WMD -0.65 puffs/day; 95%CI -1.75 to 0.45, respectively. REVIEWERS' CONCLUSIONS: Based on currently available evidence it is not possible to conclude whether dietary salt reduction has any place in the treatment or management of asthma. The results of this review do indicate an improvement in pulmonary function with low salt diet, however further large scales trials are required before any firm conclusions can be reach.

Dietary salt reduction or exclusion for allergic asthma.

BACKGROUND: There is a wide geographical variation in asthma prevalence and one explanation may be in dietary salt consumption. OBJECTIVES: To assess the effect of dietary sodium reduction in patients with asthma. SEARCH STRATEGY: A search was conducted using the Cochrane Airways Group asthma register. Bibliographies of included randomised controlled trials (RCTs) were searched for additional studies. Authors of identified RCTs were contacted for other studies. SELECTION CRITERIA: All studies were to be RCTs that involved dietary salt reduction or increased salt intake in patients with asthma. Studies of other allergic conditions such as hay fever, allergic rhinitis and eczema were considered patients with asthma were separately identified. DATA COLLECTION AND ANALYSIS: Study quality was assessed and data extracted by two reviewers. All data analysis was conducted using the Cochrane Collaboration software (RevMan 4.1.1). MAIN RESULTS: Fifty-six abstracts were identified and 15 studies were reviewed in full text. Five fulfilled the inclusion criteria. Nine were excluded. One was published in duplicate. Complete agreement was reached between the reviewers on inclusion or exclusion of all studies. All studies were small and of short duration. Data from only three could be pooled. Low sodium diet was associated with a significantly lower urine sodium excretion than normal or high salt diets. There were no significant differences in any asthma outcome between low salt and normal or high salt diets, but FEV1 was slightly higher with low salt compared to normal, WMD 0.09 L (95% confidence interval (CI) -0.26, 0.44 L, n=88), as was daily PEFR, WMD 11 l/min (95% CI -81, 103 l/min, n=78). With low compared to high salt, FEV1 was slightly higher WMD 0.22 L (95% CI -0.14, 0.59 L, n=88), as was daily PEFR, WMD 14 l/min (95% CI -41, 68 l/min, n=78). Bronchodilator use was slightly lower, WMD 0.7 puffs/day (95% CI -1.8, 0.5 puffs/day, n=62). REVIEWER'S CONCLUSIONS: Based on currently available evidence it is not possible to conclude whether dietary salt reduction has any place in the treatment or management of asthma.

Tartrazine exclusion for allergic asthma.

BACKGROUND: Tartrazine is the best known and one of the most commonly used food additives. Food colorants are also used in many medications as well as foods. There has been conflicting evidence as to whether tartrazine causes exacerbations of asthma with some studies finding a positive association especially in individuals with cross-sensitivity to aspirin. OBJECTIVES: To assess the overall effect of tartrazine (exclusion or challenge) in the management of asthma. SEARCH STRATEGY: A search was carried out using the Cochrane Airways Group specialised register. Bibliographies of each RCT was searched for additional papers. Authors of identified RCTs were contacted for further information for their trials and details of other studies. SELECTION CRITERIA: RCTs of oral administration of tartrazine (as a challenge) versus placebo or dietary avoidance of tartrazine versus normal diet were considered. Studies which focused upon allergic asthma, were also included. Studies of tartrazine exclusion for other allergic conditions such as hay fever, allergic rhinitis and eczema were only considered if the results for subjects with asthma were separately identified. Trials could be in either adults or children with asthma or allergic asthma (e.g. sensitivity to aspirin or food items known to contain tartrazine). DATA COLLECTION AND ANALYSIS: Study quality was assessed and data abstracted by two reviewers independently. Outcomes were analysed using RevMan 4.1.1. MAIN RESULTS: Ninety abstracts were found, of which 18 were potentially relevant. Six met the inclusion criteria, but only three presented results in a format that permitted analysis and none could be combined in a meta-analysis. In none of the studies did tartrazine challenge or avoidance in diet significantly alter asthma outcomes. REVIEWER'S CONCLUSIONS: Due to the paucity of available evidence, it is not possible to provide firm conclusions as to the effects of tartrazine on asthma control. However, the six RCTs that could be included in this review all arrived at the same conclusion. Routine tartrazine exclusion may not benefit most patients, except those very few individuals with proven sensitivity.